Blood AdvancesDevelopment of Luspatercept to Treat Ineffective Erythropoiesis

This “Clinical Trials & Observations” report from Blood Advances (ASH)  explores the implications of the recently approved anemia treatment luspatercept, which can now be prescribed in the second-line setting after erythropoiesis-stimulating agents (ESAs) have failed or for patients who are not eligible because of high serum erythropoietin (sEPO) levels. A downloadable visual abstract helps paint the picture as well.